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Abstract
 Artificial intelligence-based software may automaticallyBackground:
detect ischaemic stroke lesions and provide an Alberta Stroke Program
Early CT score (ASPECTS) on CT, and identify arterial occlusion and
provide a collateral score on CTA. Large-scale independent testing will
inform clinical use, but is lacking. We aim to test e-ASPECTS and e-CTA
(Brainomix, Oxford UK) using CT scans obtained from a range of clinical
studies.
 Using prospectively collected baseline CT and CTA scans fromMethods:
10 national/international clinical stroke trials or registries (total >6600
patients), we will select a large clinically representative sample for testing
e-ASPECTS and e-CTA compared to previously acquired independent
expert human interpretation (reference standard). Our primary aims are to
test agreement between software-derived and masked human expert
ASPECTS, and the diagnostic accuracy of e-ASPECTS for identifying all
causes of stroke symptoms using follow-up imaging and final clinical
opinion as diagnostic ground truth. Our secondary aims are to test when
and why e-ASPECTS is more or less accurate, or succeeds/fails to produce
results, agreement between e-CTA and human expert CTA interpretation,
and repeatability of e-ASPECTS/e-CTA results. All testing will be
conducted on an intention-to-analyse basis. We will assess agreement
between software and expert-human ratings and test the diagnostic
accuracy of software. 
 RITeS will provide comprehensive, robust andConclusions:
representative testing of e-ASPECTS and e-CTA against the current
gold-standard, expert-human interpretation.
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Introduction
Accurate and rapid identification and quantification of CT imag-
ing features indicative of early ischaemic and haemorrhagic 
stroke is required to correctly triage patients for urgent treat-
ment. However, early ischaemic brain changes can be subtle 
on non-enhanced CT (NECT) and identification requires 
training and experience1. The Alberta Stroke Program Early 
CT Score (ASPECTS) helps quantify early ischaemia on 
CT and may aid decision making prior to thrombolysis and 
thrombectomy2–4. It is particularly important to exclude 
acute intracranial haemorrhage as the cause of stroke prior to 
thrombolytic therapy since thrombolysis may worsen haemor-
rhage. Additionally, a CT angiogram (CTA) may be required 
immediately after NECT to identify patients with arterial 
obstruction who are suitable for thrombectomy. Interpretation 
of CTA also requires training and experience.
A potential solution to help interpret brain CT and CTA after 
suspected stroke is offered by e-ASPECTS and e-CTA diag-
nostic software (Brainomix Ltd, Oxford UK). This software, 
developed using machine learning, includes an automated 
ASPECTS and detection of acute haemorrhage on NECT, and a 
CTA assessment to detect large vessel obstruction (LVO) and 
collateral blood supply. e-ASPECTS is said to be as accurate as 
expert human rating of ASPECTS5,6, and the software has been 
promoted to support and accelerate stroke treatment decisions. 
However, as is the case with many diagnostic tools developed 
using machine learning7, e-ASPECTS lacks independent dem-
onstration of reliability, safety or clinical utility, especially for 
newer features of haemorrhage detection and CTA assessment8. 
It is also unclear how e-ASPECTS handles other pathologies 
which make up around 20% of patients presenting with stroke-
like symptoms (i.e. stroke mimics) such as tumours, subdural 
haematomas or infections.
The Real-world Independent Testing of e-ASPECTS Software 
(RITeS) study will independently evaluate the accuracy, reli-
ability and clinical benefit of e-ASPECTS and e-CTA software. 
Here we pre-specify the statistical analysis plan for RITeS.
Methods
Study design
We will test the accuracy of e-ASPECTS and e-CTA software 
for the automated assessment of CT scans performed acutely 
for suspected stroke among representative patients. We will 
compare e-ASPECTS/e-CTA with expert human readers who 
form the current reference standard. We will use CT scans from 
acute stroke trials that include a range of commonly encoun-
tered scan appearances including early ischaemia, haemorrhage, 
typical pre-stroke features and mimics. All scans have been rated 
by panels of experts representing many different individuals 
across these non-commercial trials. We will in addition, per-
form new human-ratings for a subgroup of the previously col-
lected scans to compare the time needed for human versus 
e-ASPECTS assessment of CT and to assess the clini-
cal impact of e-ASPECTS software on acute stroke care, i.e. 
whether it influences diagnostic confidence or alters treatment 
decisions.
Patient population
A clinically representative sample (equivalent to the patient 
population for whom e-ASPECTS or e-CTA may routinely be 
used) of baseline NECT brain and CTA scans will be selected 
from the following 10 multicentre national and international 
randomised-controlled trials (RCTs) and observational studies 
of stroke: Alteplase versus tenecteplase for thrombolysis after 
ischaemic stroke (ATTEST)9; European multicentre, randomised, 
phase III clinical trial of therapeutic hypothermia plus best medi-
cal treatment versus best medical treatment alone for acute 
ischaemic stroke (EuroHyp-1)10; Third International Stroke 
Trial (IST-3)11; Lothian study of INtraCerebral Haemorrhage 
Pathology, Imaging and Neurological outcome (LINCHPIN)12; 
Pragmatic Ischaemic Thrombectomy Evaluation (PISTE)13; 
POst-Stroke Hyperglycaemia (POSH)14; Penumbra and Reca-
nalisation Acute Computed Tomography in Ischaemic Stroke 
Evaluation (PRACTISE)15; REstart or STop Antithrombotics 
Randomised Trial (RESTART)16; Rapid Intervention with Glyc-
eryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2)17; Safe 
Implementation of Treatments in Stroke (SITS) open study18. 
These trials collectively include over 6600 individual patients 
accessible to RITeS; see Table 1 for individual trial numbers and 
details of available imaging.
All of these trials individually obtained research ethics com-
mittee approval. Consent was acquired from or on behalf of all 
recruited patients.
Baseline CT scans in these trials were scored using very simi-
lar methods (often using identical pre-validated schema, i.e. five 
of the trials used IST-3 methodology for scan assessment19, all 
studies of ischaemic stroke included ASPECTS scoring), and 
similar patient demographic baseline and outcome data were 
collected. Scan ratings were obtained by expert readers, nomi-
nated by the trials, without knowledge of any clinical baseline 
or follow-up data, follow-up scans or treatment. Expert rat-
ing included assessment for: ASPECTS2; acute ischaemia in 
brain regions other than the MCA territory1,20; acute intracra-
nial haemorrhage21; structural stroke mimics, pre-stroke brain 
changes (brain atrophy, leukoaraiosis, old stroke lesions)3 and 
image quality. Baseline CTA scans were scored for: arterial 
obstruction location and extent22; collateral extent23. 
All of these trials recorded patient demographics (e.g. age, 
sex), time from stroke onset, included some measure of stroke 
severity -National Institutes of Health Stroke Scale (NIHSS) 
for ischaemic stroke, and Glasgow Coma Scale (GCS) for 
haemorrhagic stroke, and assessed clinical outcome at 90 days 
or later.
Inclusion and exclusion criteria
We will derive separate but overlapping samples for e-ASPECTS 
and e-CTA testing from all baseline scan data available to 
RITeS. We will produce a STARD-type (Standards for Report-
ing Diagnostic Accuracy Studies) flow chart24 to show reasons 
for inclusion/exclusion of cases and successful/non-successful 
scan assessment by human-readers and software for all patients 
available to RITeS.
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Sample for e-ASPECTS evaluation. There are no precise data 
for the true case-mix of patients initially assessed for presumed 
stroke, and for whom hospital admission staff may decide to use 
e-ASPECTS and e-CTA software to assess treatment eligibil-
ity. Pooled data from the major thrombolysis and thrombec-
tomy RCTs will be similar to the case-mix considered for 
these treatments but may include patients with more severe 
stroke than those seen in routine practice and will not include 
patients who present late4,25. Conversely, patients with haem-
orrhagic stroke are most likely to be severely affected by stroke 
symptoms26, and a proportion may be too sick to be appropriately 
represented in trials. The Sentinel Stroke National Audit Pro-
gramme (SSNAP) provides routinely collected UK data for all 
patients ultimately diagnosed with stroke in England, Wales and 
Northern Ireland and includes many patients with minor symp-
toms or delayed/uncertain time of presentation who would not 
routinely be considered for thrombolysis or thrombectomy27. 
Importantly, all of these data sources only include patients after 
excluding structural stroke mimics. RIGHT-2 recruited patients 
at first contact with ambulance staff in the community and 
reported 26% stroke mimics17. A prospective single-centre study 
of patients with suspected stroke following stroke expert review 
after arrival at hospital found a similar proportion of mimics28. 
Additionally, in up to 7% of patients with stroke, it is only pos-
sible to obtain imaging of poor quality due to patient movement, 
beam hardening artefacts or variable patient orientation in the scan-
ner, all of which may influence the performance of e-ASPECTS 
and e-CTA software3,11. Finally, the sensitivity and specificity of 
diagnostic tests may vary with prevalence29. 
To derive a ‘real-world’ dataset from all patients available to 
RITeS, and simultaneously maximise sample size, we will 
therefore: 
1) Include all structural stroke mimics for e-ASPECTS 
testing (since this will be far less than 26%, but see 
planned sensitivity analyses for our primary outcomes 
below)
2) For the remainder of included patients (i.e. non- 
mimics), aim for sex and age mix, stroke severity and 
Table 1. Clinical stroke trials with baseline CT scans available for inclusion in RITeS.
Stroke Trial Number patients Baseline CT Assessment
Stroke 
Type Trial Type Other Scans
Follow-up 
Data
ATTEST 104 ASPECTS Isch RCT – IV alteplase or 
tenecteplase
CT at 24–48 hrs 2 & 90 days
EuroHyp 98 As per IST-3, excluding CTA. Isch RCT – systemic 
cooling to 34-5°C for 
24 hours or control
CT/MRI at day 5 0–7 & 90 days
IST-3 3035 Ischaemia extent & location, 
ASPECTS, swelling, atrophy, 
leukoaraiosis, old stroke 
lesions, arterial patency & 
collateral scores on CTA, scan 
quality3.
Isch RCT – IV alteplase or 
control
Baseline CTA (in 
~270) 
CT/MRI at 24–48 hrs
7 days & 6-
months
LINCHPIN 947* Location & size of intracerebral 
haemorrhage
Haem Observational cohort 
study
MRI at 3 months Post-mortem
PISTE 65 As per IST-3. Isch RCT – IV alteplase 
and thrombectomy or 
IV alteplase alone
Baseline CTA 
CT/MRI at 22–36 hrs
2 & 90 days
POSH 113 Ischaemia volume on CT, 
ASPECTS, arterial patency on 
CTA
Isch Observational study CT at 24–48 hrs
PRACTISE 271 As per IST-3. Isch RCT – Multimodal CT 
imaging (CT + CTA + 
CTP) or CT alone
Baseline CTA (in 
50%) 
CT/MRI at 24 hrs
1, 7 & 90 days
RESTART 537 Location & size of 
haemorrhage, atrophy, 
leukoaraiosis, old stroke 
lesions, scan quality
Haem RCT – restart or avoid 
antiplatelets after 
haem stroke
MRI pre-
randomization (in 
550)
1–3 years
RIGHT-2 1149 As per IST-3. Isch RCT – ultra-early 
transdermal GTN or 
control
CT at 24–48 hrs 4 & 90 days, 1 
year
SITS Open 293 ASPECTS, swelling, arterial 
patency on CTA
Isch Controlled study 
-thrombectomy vs 
control
Baseline CTA (in 
~5%) 
CT/MRI at 22–36 hrs
1, 7 & 90 days
* Ongoing at time of data collection.
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time since symptom onset similar to SSNAP, pooled 
thrombolysis/ thrombectomy RCT data, and haemor-
rhagic stroke registry data.
3) Not exclude imaging based on quality.
The most recent SSNAP annual dataset (Apr 2018-Mar 2019) 
identified 87,635 patients presenting acutely with stroke and had 
93% data completion. Of these patients, 47.8% were female, 
median age was 77 years, 87.1% of strokes were ischaemic, 12.4% 
were haemorrhagic (0.4% unknown), and the median NIHSS 
was 5. For 69.4% of patients, the time of symptom onset was 
known and the median time from stroke onset to baseline scan 
in these patients was 4 hours and 2 minutes30. A pooled analysis 
of nine thrombolysis RCTs by the Stroke Thrombolysis Trialists’ 
Collaborative (STTC) group included 6,756 patients of whom 
45% were female, the mean age was 71 years, the mean NIHSS 
was 12, and the mean treatment delay was 4 hours25. A pooled 
analysis of seven thrombectomy RCTs by the Highly Effective 
Reperfusion evaluated in Multiple Endovascular Stroke Tri-
als (HERMES) collaboration included 1764 patients of whom 
47% were female, the median age was 67 years, the median 
NIHSS was 17, and the mean time from onset to randomisa-
tion was 3 hours4. A comprehensive, community-based audit of 
haemorrhagic stroke in Scotland (The Lothian Audit of the Treat-
ment of Cerebral Haemorrhage, LATCH) included 137 patients 
with primary haemorrhagic stroke of whom 55% were female, 
the median age was 79 years, and the median Glasgow Coma 
Scale at presentation was 1331,32.
To ascertain the representativeness of the non-mimic cases 
within the RITeS dataset, we will report demographic and clini-
cal data as per SSNAP, STTC, HERMES and LATCH data (see 
Table 2). We will report absolute differences, 95% confidence 
intervals and p-values for comparisons. We will also present 
continuous data components using overlapping histograms.
To ascertain the representativeness of relevant radiologi-
cal features in RITeS, we will also report the features listed in 
Table 3.
Sample for e-CTA evaluation. The main indication for acute 
stroke CTA currently is to determine if the patient is suitable 
for thrombectomy; such patients are more likely to have a more 
severe ischaemic stroke and to be younger than the median age of 
all stroke. CTA is used at some sites prior to thrombolysis but this 
is not universal and there is no standard or widely agreed prac-
tice. There is also less CTA data available in RITeS for testing. 
We will therefore include all patients for e-CTA testing from all 
available RITeS trials where CTA was performed routinely at 
baseline, i.e. we will not select a representative subsample.
Sample size considerations
Tests of diagnostic accuracy are difficult to power and benefit 
from maximising the sample size33. In addition, sample size cal-
culations may be inappropriate in this setting34. We therefore 
aim for the largest representative sample possible within avail-
able resources. However, to allow direct comparison with pre-
vious work, we estimated that to confirm that e-ASPECTS 
software is non-inferior for an “MCC (Matthews Correlation 
Coefficient) better than random” (to expert human calcula-
tion of ASPECTS using an MR diffusion-weighted imaging 
reference standard: e-ASPECTS correlation 0.44 versus 0.38 
for experts), based on 34 patients35, requires a sample size 
of 494 scans – at 5% non-inferiority limit with 80% power 
and at 5% significance level. Therefore, we have set the minimum 
sample size for our primary outcome at 500 unique patient CT 
brain scans. Up to 31% of scans may fail to give an e-ASPECTS 
result for technical reasons36, therefore we will inflate the mini-
mum sample to 725 scans (i.e. 1/0.69 × 500) to ensure the suc-
cessfully processed sub-sample includes the requisite minimum 
500 scans. However, this minimum will have limited power for 
subgroup analyses (e.g. on pre-stroke brain changes, by age or 
Table 2. Planned assessment of demographic and clinical data for non-stroke mimic cases within the 
RITeS dataset, and comparison with other datasets.
Clinical Feature RITeS dataset SSNAP dataset
STTC 
dataset
HERMES 
dataset
LATCH 
dataset
Total patient number 87,635 6,756 1,764 137
Female sex 48% 45% 47% 55%
Age, years 77 (66-85) 71 (13) 67 (57-76) 79 (67-83)
Aetiology
Ischaemia 87% 100% 100% -
Haemorrhage 12% - - 100%
NIH Stroke Scale 5 (2-11) 12 (7) 17 (13-21) -
Glasgow Coma Scale - - - 13 (9-15)
Time from stroke onset, hours 4 (2-11) 4 (1.2) 3 (2-4) -
Note: Data are percentage, median (inter-quartile range), or mean (standard deviation) as appropriate.
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stroke severity strata) and the study cited for our power calcula-
tion used individual ASPECTS regions rather than individual 
patients to power their analysis, which due to lack of independ-
ence between individual ASPECTS regions, may be flawed35. 
Therefore we will process every available scan to derive the 
largest possible sample for testing.
Image processing
All CT scans will be processed by the RITeS team as follows: 
1) In DICOM (Digital Imaging and Communications in 
Medicine) format
2) On the cloud-based e-ASPECTS platform available at 
https://brainomix.com
3) Anonymised prior to web upload to remove patient 
identifiers, but retaining original trial identifiers, 
using modiCAS DICOM anonymizer (Erlangen, 
Germany).
4) A person, trained in CT scan handling, will manually 
select the relevant scan for each patient using four 
criteria: 
I. First CT scan acquired after the patient 
reached hospital, if more than one available.
II. Ideally native images (i.e. non-reformatted) 
acquired axially, but reformatted scans will be 
accepted if native imaging not available.
III. The thinnest CT slices if more than one 
image set available.
IV. Scans acquired using a soft-tissue kernel.
At this stage, all scans meeting these criteria will be 
processed agnostic of patient or imaging characteristics. 
Scan selection for entry into the representative 
RITeS dataset will occur only once processing is 
complete, blind to imaging appearances and software 
results (see below).
5) Scans will be batched into zip files of 10+ scans 
and uploaded to the Brainomix cloud-based platform.
6) Affected side information will not be included at 
this processing stage but will be entered separately 
later for a proportion of cases.
7) Any scan upload or processing failures will be recorded 
in a spreadsheet.
Table 3. Planned assessment of radiological characteristics of the entire RITeS dataset.
Radiological Finding N (%) or Median (IQR)
Ischaemic brain changes
None
Subtle (e.g. loss of grey-white margins)
Obvious (e.g. hypoattenuation relative to 
normal white matter +/- swelling)
Ischaemic location
MCA territory
Other cerebral
Brainstem or cerebellum
Cortical
Subcortical
Hyperattenuating arteries List location
Haemorrhage location
Deep
Lobar
Intraventricular
Extra-axial
Structural stroke mimic List type (e.g. tumour, inflammation, collection)
Pre-stroke brain changes
Atrophy
Leukoaraiosis
Old Stroke lesions
CT slice thickness
Thin (≤ 1 mm)
Medium (> 1 mm ≤ 5 mm)
Thick (> 5 mm)
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8) Results will be exported from the Brainomix platform, 
using the standard export function and stored 
securely offline in .csv format.
Primary outcomes
1. Difference in ASPECT scores provided by e-ASPECTS 
versus expert human readers.
2. Diagnostic accuracy of e-ASPECTS versus expert 
human readers for identifying the cause of stroke 
symptoms (i.e. ischaemia, haemorrhage, other).
Secondary outcomes
1. Proportion of scans successfully versus unsuccess-
fully processed by e-ASPECTS (i.e. where ASPECTS 
results are provided or not provided), factors associ-
ated with e-ASPECTS processing success and result 
accuracy.
2. Proportion of ICA-MCA occlusion versus normal 
ICA-MCA axis correctly identified by e-CTA, accu-
racy of e-CTA for detecting any intracranial obstruc-
tion, difference in CTA collateral scores provided by 
e-CTA versus expert human readers.
3. Repeatability of e-ASPECTS and e-CTA results on a 
subset of scans presented twice.
Tertiary outcomes
1. Difference in haemorrhage size and location results 
provided by e-ASPECTS versus expert human 
readers.
2. Potential clinical impact of e-ASPECTS and e-CTA 
on routine acute stroke care, whether: 
a. knowledge of ASPECTS conveyed using 
e-ASPECTS visual overlay on imaging 
influences diagnostic confidence or alters 
treatment decisions,
b. use of e-ASPECTS/e-CTA alter the time 
required for scan interpretation, and
c. e-ASPECTS or e-CTA results are associated 
with outcome after ischaemic stroke.
Dissemination of results
We will include all primary and secondary outcomes in the 
primary RITeS publication.
Tertiary outcomes require additional expert-human data to be 
collected and will therefore be reported separately, subsequent 
to the primary RITeS publication.
Statistical analysis
Analysis principles and general considerations
• Primary and where appropriate, secondary outcome 
testing will be conducted on an ‘intention-to-analyse’ 
basis irrespective of whether scan processing was 
successful or not
◦ Processing will be considered successful when 
an ASPECTS (0-10) or CTA result (occlusion/
no-occlusion or scalar collateral score) is 
provided, or when arterial hyperattenuation 
or haemorrhage is detected.
◦ We will record all software failures whether 
these occur at the scan upload, scan processing, 
or results output stage.
• We will use mean (standard deviation, SD) or 
median (inter-quartile range, IQR) to represent the 
distribution of parametric and non-parametric data, 
respectively. We will use n (%) for categorical data.
• Where possible, we will use diagnostic accuracy 
statistics as the principal method in RITeS for comparing 
software and expert human results. With expert human 
results as the reference standard, we will calculate 
true/false positive/negative cases (TP, FP, TN, FN, 
respectively) and derive sensitivity (TP/TP+FN), 
specificity (TN/TN+FP), positive predictive (TP/TP+FP), 
negative predictive (TN/TN+FN), and accuracy (TP+TN/
TP+TN+FP+FN) percentages as standard. We will 
calculate 95% confidence intervals for each using the 
Wilson score method37. 
◦ For all diagnostic accuracy testing we 
will include random-effects meta-analysis 
modelling of individual patient data (i.e. a 
one-step meta-analysis) to provide overall 
estimates of sensitivity and specificity, to 
assess variation within and between the 10 
RITeS studies, and to account for clustering of 
individual study results38,39.
◦ For each of the 10 RITeS studies, we will 
use the PROBAST method for assessing risk 
of bias in diagnostic modelling40. 
• For all comparisons of software and expert human 
results, we will review side of affected brain data 
to ensure ASPECTS and CTA results are correctly 
matched for each cerebral hemisphere, i.e. matched 
results require same score and side. We will separately 
test whether knowledge of affected side impacts 
the accuracy of e-ASPECTS results, see secondary 
outcomes below.
• Bland-Altman plots41 will be used to visually compare 
software and expert human results, comparing mean 
score differences to assess the magnitude, direction 
and distribution of error and will use ± 1.96 SD to 
determine the range of agreement42. For software and 
expert human results to be considered equivalent, 
we will set maximum clinically acceptable limits of 
agreement for individual scores, specified in the relevant 
sections below.
• Krippendorff’s Alpha43 (K-alpha) will be used to 
assess reader (human-human and human-software, 
as necessary) agreement. K-alpha is generally more 
robust than kappa in this context since it can handle 
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categorical and ordinal data, works where there is 
missing data, adjusts for small sample sizes, and 
includes multiple observers simultaneously43,44. K-alpha 
results are interpreted similarly to kappa with scores 
ranging from -1 (perfect disagreement) to +1 (perfect 
agreement). We will therefore also use the Landis 
and Koch method for interpreting K-alpha results (as 
commonly used for kappa): 0.00–0.20=slight agreement, 
0.21–0.40=fair agreement, 0.41–0.60=moderate 
agreement, 0.61–0.80=substantial agreement and 
0.81–1.00=almost perfect agreement45.
• Other specific statistical tests are listed in the 
following sections.
• For multivariable testing, we will check for 
multicollinearity between included variables by 
identifying variance inflation factors (VIF) >5. Where 
multicollinearity is detected, we will run separate (but 
otherwise equivalent) multivariable regression models 
for each of the internally correlated variables.
• We will not impute but will report missing data 
(proportions of data missing for each variable and 
observations not included in analyses).
• We will use SPSS, IBM Corporation (Armonk, USA) 
and/or R (https://www.r-project.org/) statistical software 
for all analyses. We will preferentially report 95% 
confidence intervals, but where appropriate, we will 
report p-values.
Primary outcomes
For these evaluations of e-ASPECTS, we will use a 
representative RITeS sample of NECT.
In two analyses, we will compare e-ASPECTS results to 
those provided by expert human readers for the assessment of 
non-enhanced brain CT acquired at baseline among patients 
presenting acutely with symptoms of stroke.
Representative sampling for e-ASPECTS testing of primary 
outcomes. Where clinical or demographic features are differ-
ent to the comparator SSNAP/STTC/HERMES datasets (i.e. 
RITeS values should be within the range provided by the other 
datasets), we will use stratified random sampling to remove 
select cases (which are over-representing these features) to 
reduce these differences while maintaining the maximum sam-
ple size from the data available to RITeS. For example, if RITeS 
has 42% female patients and a median NIHSS of 19, we would 
identify all male patients with a high NIHSS and randomly 
remove subsets of these until the sex ratio and NIHSS are within 
the desired ranges. We will not select cases on the basis of the 
radiological features in Table 3.
To assess the impact of factors beyond our control which 
might affect the representativeness of our sample, we will per-
form sensitivity analyses of our primary outcomes for the 
following randomly selected subgroups: 
1. With balanced representation from all RITeS trials, 
i.e. we will exclude surplus cases for trials which are 
relatively over-represented (more than double the 
median trial contribution).
2. Where non-stroke mimics represent 26% of the total 
sample.
1. Difference in ASPECT scores of e-ASPECTS and expert 
human readers. We will compare e-ASPECTS and expert human 
results using overlapping histograms and Mann-Whitney U test-
ing to assess the distribution of results, and Wilcoxon signed 
rank testing and Bland-Altman plots to assess pairwise agree-
ment for each case. For results to be considered equivalent on 
Bland-Altman testing, we expect the range of agreement to be 
within ± 2 ASPECTS points. This is an arbitrarily derived but 
clinically meaningful difference that might lead to alterations 
in treatment for individual patients based on the thresholds 
presented below. We will also use K-alpha statistics to assess 
software-human reader agreement for these scalar data.
We will classify e-ASPECTS and expert-human scores into 
three groups to assess diagnostic accuracy at the follow-
ing clinically relevant cut-points, and present a summary 
(receiver-operating characteristic) ROC curve: 
1) ASPECTS 10 (normal) versus ASPECTS 0-9 
(abnormal)
2) ASPECTS 0-7 versus 8-102.
3) ASPECTS 0-5 versus ASPECTS 6-104.
To compare with previous work, we will use Matthews cor-
relation coefficient (MCC), and test non-inferiority between 
e-ASPECTS and expert-human scores5,35. We will calculate MCC 
as (TPxTN)-(FPxFN)/√(TP+FP)(TP+FN)(TN+FP)(TN+FN)46. 
We will set our non-inferiority margin at 5%. Thus using the two 
one-sided test (TOST) procedure, we will establish non-infe-
riority, using the following formula: at the α=5% significance 
level, if the lower limit of a (1-2α) × 100% (i.e. 90%) confi-
dence interval for the difference (e-ASPECTS minus expert-
human results) is above -5%. The confidence interval is set 
at (1-2α) rather than the usual (1-α) because the method is 
equivalent to performing two one-sided tests47,48.
2. Accuracy of e-ASPECTS versus expert human readers for 
identifying cause of stroke symptoms. We will compare the 
diagnostic accuracy of e-ASPECTS software and expert human 
readers (at baseline, blind to all other clinical data including 
further imaging) for three groups against the reference stand-
ard, human-expert opinion using all available follow-up data 
including further imaging:
1) Identifying features of ischaemic stroke (including 
ischaemic lesions in any brain location and/or 
intracranial hyperattenuating arteries)
2) Identifying haemorrhage, and
3) Identifying any structural causes of stroke symptoms 
on baseline imaging (including mimics).
In addition, to aid clinical understanding and real-world appli-
cability, we will summarise all primary outcome results using 
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normalised frequencies. Thus we will present results as pro-
portions of 1000 individual patients, i.e. a test sensitivity of 
90% would be presented as: the test will detect disease in 900 
of 1000 patients with the disease, but 100 patients with the 
disease will be missed by the test49.
Secondary outcomes
1. e-ASPECTS processing success and factors influencing 
accuracy. To present the most complete picture available, we 
will use the entire RITeS sample for these analyses (i.e. not just 
the representative sample) but we will also include a sensitivity 
analysis of the representative sample.
We will report the proportion of scans successfully and unsuc-
cessfully processed by e-ASPECTS and collate reasons cited 
by e-ASPECTS for any processing failures. We will use sum-
mary statistics to describe and compare the subgroups of 
scans that were successfully versus unsuccessfully processed. 
This will include patient and radiological factors (see Table 4).
To determine the influence of patient and radiological factors 
on the accuracy of ASPECTS results produced by e-ASPECTS 
software, we will perform multivariable ordinal logistic regres-
sion using the variables pre-specified in Table 5. The dependent 
variable will be the absolute difference in ASPECTS between 
e-ASPECTS and expert human readers (i.e. scalar, 0-10).
For any variables found to be significantly associated with poorer 
e-ASPECTS results on regression testing (i.e. independently 
associated with greater difference between e-ASPECTS and 
expert human reader scores), we will also calculate and com-
pare diagnostic accuracy figures (as above) for each of the 
subgroup arms (for these analyses only, continuous data will 
be dichotomised as per Table 5).
Finally, to account for (the as yet unknown) covariates that 
alter e-ASPECTS diagnostic accuracy figures, we will derive 
covariate-adjusted ROC curves (AROC)50.
2. Identification of CTA obstruction and collateral scoring by 
e-CTA versus expert human readers. There are two components 
to the e-CTA output: 
1. Where ICA-MCA occlusion is identified, the loca-
tion is categorised either proximal (ICA/proximal 
MCA) or distal (distal MCA). Other arteries are not 
assessed.
2. MCA collateral scoring (modified Tan et. al. 2009)51 
is given for all cases on the scale 0 = no collaterals 
(<10% of affected MCA territory compared to contra-
lateral side), 1 = poor (10–50%), 2 = good (50–90%), 
3 = excellent (>90%) collaterals (i.e. includes normal 
scans).
Table 4. Planned univariable comparison of scans successfully versus unsuccessfully processed by 
e-ASPECTS.
Variable Successfully Processed
Not Successfully 
Processed
Absolute differences, 
95% CI and p-value
Patient age (median, IQR)
Patient sex (n, %)
Minutes from stroke onset to scan (median, 
IQR)
NIHSS (median, IQR)
Stroke aetiology (n, %): 
       •   Ischaemia MCA territory
       •   Ischaemia elsewhere
       •   Haemorrhage
       •   Mimic
Presence of pre-stroke brain changes (n, %): 
       •   Atrophy
       •   Leukoaraiosis
       •   Old stroke lesions
CT slice thickness (n, %): 
       •   ≤ 1 mm
       •   > 1 mm ≤ 5 mm
       •   > 5 mm
Image quality (n, %): 
       •   Good quality
       •   Movement artefacts
       •   Streak artefacts
       •   Patient malposition
Note: IQR = Inter-quartile range. MCA = middle cerebral artery. NIHSS = National Institutes of Health Stroke Scale.
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The expert human rated CTAs available to RITeS include simi-
lar scoring methods for comparison with e-CTA outputs, but 
also additional measures such as degree of arterial patency 
(i.e. from fully patent through increasingly obstructed to 
occluded)22.
We will test three components:
1. The proportion of scans where e-CTA and expert 
humans agree or disagree in the assessment of proximal 
versus distal ICA-MCA axis occlusion, see Table 6. 
We will use K-alpha statistics to compare agreement 
for ICA-MCA axis occlusion detected by e-CTA and 
expert human readers.
2. Diagnostic accuracy of e-CTA for detecting abnormal 
versus normal intracranial CTA using the methods 
described above. Abnormal will include both 
arterial obstruction (partially blocked) and arterial 
occlusion (completely blocked) for 11 named intracranial 
arterial segments, i.e. not just ICA or MCA; we will 
also assess the anterior and posterior cerebral arteries 
(ACA and PCA, respectively), the vertebral and basilar 
arteries (five left, five right, one central).
3. Agreement on collateral score. Most of the expert 
collateral scoring available in RiTeS used the Miteff 
method (three-point scalar = good, moderate, poor)23, 
rather than the modified Tan method (4-point scalar 
= excellent, good, poor, none) but as ordinal scores, 
these are comparable. There are three ways to compare 
the scores (see Table 7). We will test all variations for 
agreement. We will use K-alpha statistics to check the 
extent of agreement between e-CTA and human-rated 
results for the scalar collateral scoring.
3. Repeatability of e-ASPECTS and e-CTA results. We will 
select a small subgroup of RITeS scans for repeat e-ASPECTS 
and e-CTA testing. These subgroup sizes were arbitrarily 
chosen within available time and scan processing resource 
limitations.
We will include separate assessments of ASPECTS (n=100), 
haemorrhage detection (n=20) and CTA scoring (n=20). 
We will select scans for repeat testing, blind to all previ-
ous results (from e-ASPECTS, e-CTA or expert human read-
ers) except knowledge of previous successful processing by 
e-ASPECTS or e-CTA. To ensure this subsample remains largely 
representative of the available stroke trial mix, we will use 
cluster random sampling, as follows. Each stroke trial represents 
a cluster. Random samples will be drawn from each cluster in 
numbers to match individual stroke trial proportions in the 
entire representative sample until the total numbers required are 
reached for each of the separate assessment groups, total n=140.
To limit the possibility of previously calculated results being 
presented again (rather than freshly derived from the ‘new’ 
scan), selected scans will have all unique identifiers replaced 
prior to repeat e-ASPECTS/e-CTA processing. This includes 
original trial IDs and any other DICOM information that 
uniquely identifies individual scans (e.g. accession number, 
series/scan unique identifiers).
We will compare original and repeat results for agreement, as 
per Table 8. We will use Mann-Whitney U tests to compare sca-
lar and non-parametric continuous group data, and K-alpha 
to compare paired scan results.
Tertiary outcomes
1. Haemorrhage quantification by e-ASPECTS versus expert 
human readers. We will use all RITeS NECT containing acute 
haemorrhage for this analysis. This includes scans acquired 
from haemorrhagic stroke trials (i.e. brain haemorrhages with 
or without intraventricular extension) in addition to scans 
classed as mimics in ischaemic stroke trials (e.g. subdural or 
subarachnoid haemorrhages).
Table 5. Variables for multivariable analysis and subgroups for diagnostic accuracy testing.
Clinical Characteristics Imaging Findings Imaging Technique
Age
≤60 years
ASPECTS
<6
CT slice thickness
≤1 mm
>60 years ≥6 > 1 mm
NIHSS
0–6
Infarct Location
MCA territory
Poor patient positioning
Yes 
 
No
7–12 Elsewhere
>12
Atrophy, Leukoaraiosis, 
Old stroke lesion
Yes 
 
No
Time from stroke 
onset to scan
<3 hours
3+ hours
Imaging artefact 
(movement or streak)
Knowledge of 
affected side
Yes 
 
No
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Table 7. Options for comparing modified Tan (e-CTA) and Miteff methods (human rated) of MCA 
collateral scoring.
Modified Tan used by e-CTA 
to grade collaterals Miteff comparison 1 Miteff comparison 2 Miteff comparison 3
3 = Excellent (>90%)
Good
Good Good
2 = Good (50–90%)
Moderate
Moderate
1 = Poor (10–50%) Moderate
Poor
0 = None (0–10%) Poor Poor
Table 8. Planned results for e-ASPECTS and e-CTA repeatability testing.
Tested Component Result
e-ASPECTS, ischaemia
N, % with matched ASPECTS results
N, % for each of 1–10 point ASPECTS difference
Median, IQR for difference in scores
e-ASPECTS, haemorrhage
N, % with matched location results
N, % for each of 22 named regions
Median, IQR for comparison of haemorrhage volumes 
e-CTA, obstruction N, % with matched ICA-MCA proximal vs distal results
e-CTA, collateral scoring
N, % with matched collateral scores
Median, IQR for comparison of collateral scores
Note: ICA = internal carotid artery. MCA = middle cerebral artery.
Table 6. Comparison of ICA-MCA axis occlusion identified by e-CTA and 
expert-human groups.
    Human Readers 
e-CTA Proximal Occlusion Distal Occlusion TOTAL
Proximal 
Occlusion
Distal 
Occlusion
TOTAL
Note: All results n (%). Proximal = ICA or proximal MCA (M1). Distal = distal MCA 
(M2+).
Haemorrhage will be quantified by location and extent as 
follows.
Haemorrhage location 
Haemorrhage location will be defined by side and gross ana-
tomical regions of the brain affected including cerebral lobes 
(i.e. frontal, parietal, temporal, occipital), basal ganglia, brain-
stem, cerebellum, or extra-axial compartment (i.e. intra- 
ventricular, subarachnoid, subdural, extra-dural). We will convert 
e-ASPECTS haemorrhage detection overlay to these same 22 
(11 per side) categories following visual review, blinded to 
human-reader results.
We will look at differences in the regions (and their number) 
identified by expert humans and e-ASPECTS and if the data are 
amenable, consider using methods that account for multiple 
concurrent haemorrhage sites per patient52.
Haemorrhage extent 
Haemorrhage extent will require a comparison of haemorrhage 
volume calculated at the voxel level (e-ASPECTS) and haem-
orrhage dimensions used to estimate volume (i.e. the ABC/2 
score21,53, human readers). We will use Bland-Altman test-
ing (expected range of agreement to be within ± 10 mm3) and 
K-alpha statistics to test agreement between e-ASPECTS and 
human-rated results.
2a. Impact of e-ASPECTS on diagnostic confidence and treat-
ment decisions. We will invite stroke and hospital admission 
physicians with a range of experience to complete an online 
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questionnaire including RITeS NECT and relevant clini-
cal scenarios, similar to previous work conducted by RITeS 
members1,54. We will compare responses for readers before and 
after ASPECTS is calculated (i.e. with and without e-ASPECTS 
overlay) to assess whether ASPECTS alters confidence in stroke 
diagnosis and determine its influence on management decisions.
RITeS cases with the following range of relevant radiological 
findings will be selected: with obvious, subtle and no ischaemic 
brain lesions (and a range of ASPECTS results); with and with-
out hyperattenuating arteries; with subtle brain and extra-axial 
haemorrhage; with and without pre-stroke brain changes.
The questionnaire will contain 24 cases including some rep-
etition of the same NECT with and without e-ASPECTS over-
lay. Specifically, we will include 10 cases shown with and 
also without e-ASPECTS overlay. To limit reader recognition 
of repeat cases, these images will be modified (e.g. left-right 
reversal, removal of any visible extracranial image components) 
and presented in a non-sequential order. We will also include 
two unique cases with and two unique cases without e-ASPECTS 
overlay; each of these 4 cases will be displayed only once. Thus 
12 cases will be presented with and 12 without e-ASPECTS over-
lay. A unique clinical history will be provided for all 24 cases 
but we will limit clinical variability between repeat cases with 
and without e-ASPECTS overlay. Each case will include a panel 
of JPEG images representing the whole brain. Repeat images 
with and without e-ASPECTS overlay will include identical 
slices.
We will include up to three questions for each case:
1. Is the e-ASPECTS overlay helpful?
• Yes
• No
2. Given the clinical history and the images presented, 
would you
• Treat the patient immediately with IV 
alteplase (+/- refer for thrombectomy where 
available)
• Refer the patient immediately for thrombec-
tomy without IV alteplase
• Not treat the patient with IV alteplase or 
thrombectomy but transfer to the acute stroke 
ward
• I’m not sure, I’d first ask for a neuroradiology 
opinion
• I’m not sure, I’d like to do more imaging 
such as angiography, perfusion imaging or 
MRI (not available here)
3. How confident are you with this decision?
• Very unsure
• Unsure
• Sure
• Very sure
We will present these results as per Table 9, and visually in bar 
charts. We will compare results for the following subgroups in 
univariable analysis (chi-squared statistics): with versus with-
out e-ASPECTS overlay, more versus less experienced read-
ers, obvious versus subtle or no ischaemic lesion, with versus 
without haemorrhage, with versus without hyperattenuated 
arteries, with versus without leukoaraiosis, atrophy or old 
stroke lesions.
Table 9. Planned results for effect of e-ASPECTS on diagnostic confidence and treatment decisions questionnaire.
Question Total, n (%)
Subgroups: 
e-ASPECTS overlay, reader experience, visible 
ischaemic lesion, haemorrhage, hyperattenuating 
arteries, leukoaraiosis, atrophy, old stroke lesions
Absolute differences, 
95% CI and p-value
With n (%) Without n (%)
Found e-ASPECTS overlay helpful
Decision
Treat patient with thrombolysis/
thrombectomy
No acute treatment
Request further radiological input
Confidence in decision
Very unsure
Unsure
Sure
Very sure
Note: Table truncated for presentation of subgroups.
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2b. Use of e-ASPECTS/e-CTA and time required for scan inter-
pretation. We will select 100 NECT and 50 CTA from all RITeS 
cases that have been successfully processed by e-ASPECTS or 
e-CTA software, respectively and where expert human and soft-
ware results match (to limit the likelihood that one test group is 
disadvantaged by known or unknown factors that make scan 
reading more difficult for either group). We will use strati-
fied random sampling to ensure relevant scan appearances are 
equally represented as follows:
• From all available NECT with valid e-ASPECTS 
result we will create three strata
   i.   No acute ischaemic lesion (i.e. ASPECTS = 10)
  ii.   Small acute ischaemic lesion (ASPECTS 6-9)
 iii.    Medium-large acute ischaemic lesion (ASPECTS 
0-5)
• From all available CTA with valid e-CTA result we 
will create three strata
   i.   No arterial obstruction
  ii.   Proximal ICA-MCA obstruction
 iii.   Distal MCA obstruction
We will randomly sample similar numbers (i.e. one-third) 
from each of the three NECT and CTA strata (therefore ~33 
cases for each NECT stratum and ~16 for each CTA stratum).
We will examine the performance of e-ASPECTS/e-CTA software 
versus: 
a. Radiology/stroke physician trainees, front-of-house 
clinicians (non-experts)
b. Experienced stroke physicians or neuroradiologists 
(experts)
We aim to include a minimum of five expert and five non-expert 
readers. Each reader will be shown a unique random 10% selec-
tion (10 NECT and 5 CTA) of the cases on a PACS (picture 
archiving and communication system) workstation suitable 
for clinical review of DICOM imaging. If more than 10 read-
ers are recruited to the study, we will allow repeat reading 
of cases. Readers will be asked to fully evaluate CT and CTA as 
required for routine stroke care using a standard proforma. Full 
evaluation will include assessment for all potential causes of 
stroke symptoms in any intracranial location (NECT – ischaemic 
brain lesion including ASPECT scoring, hyperattenuating 
artery sign, haemorrhage, mass lesion) and identification of 
arterial obstruction that might cause ischaemic stroke (CTA 
– including collateral scoring when relevant). All scan ratings 
will be performed blind to clinical characteristics, prior 
human reading and prior e-ASPECTS/e-CTA software results.
An observer will record the time taken (in seconds) for full 
NECT and CTA evaluation, as well as the time needed for 
ASPECT and CTA obstruction scoring alone. Software times 
will be measured from initiation of the software prior to scan 
loading to receipt of a valid output. Valid outputs include either 
an ASPECT score, identification of a hyperattenuated artery, or 
determination of arterial patency (i.e. to ensure a fair comparison, 
software errors will be excluded from this analysis).
We will compare the time needed for human (all, expert 
only, non-expert only) and software derived ASPECTS and 
CTA obstruction/collateral scoring separately in univariable 
analyses, i.e. Mann-Whitney U testing.
2c. Association between e-ASPECTS or e-CTA results and 
clinical outcome after stroke
We will use the entire RITeS samples of NECT and CTA for 
these analyses but also perform sensitivity analyses using the 
representative NECT sample.
In separate multivariable analyses, we will test whether the three 
main software outputs of e-ASPECTS (ASPECTS result) and 
e-CTA (ICA-MCA axis occlusion, MCA territory collat-
eral score) are independently associated with stroke outcome. 
We will include the following variables in each model since 
these are already known to be associated with outcome after 
stroke: age, NIHSS, time from stroke onset, treatment with 
alteplase and/or thrombectomy (vs no treatment). The dependent 
variable in each model will be functional outcome after 
stroke. Assessment of functional outcome after stroke var-
ies among the RITeS trials and includes either the modified 
Rankin Score (mRS) at 90 days, or the Oxford Handicap Scale 
(OHS) at 6 months from stroke onset. Both mRS and OHS are 
7-point scalar ranging from normal (0) through increasing dis-
ability (1–5), to death (6). We will use multivariable ordinal 
logistic regression to calculate common odds ratios for good 
outcome, presented as per Table 10.
Table 10. Planned ordinal regression analysis results with 3–6-month post-stroke outcome as dependent variable.
Variable Raw Data N (%) or Median (IQR) Odds Ratio, OR 95% Confidence Interval p-value
Age, years
NIHSS
Time from stroke onset, minutes
Treated with alteplase +/- thrombectomy
Software-derived result*
Note: NIHSS = National Institutes of Health Stroke Scale, IQR = Inter-quartile range.
* Either ASPECTS result, presence/absence of ICA-MCA axis occlusion, MCA collateral score.
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Future data availability
In general, clinical imaging data in DICOM format are diffi-
cult to fully anonymise and are not routinely available for open 
sharing. Other clinical trial data may be available.
When RITeS data become available, these will be included here:
https://datashare.is.ed.ac.uk/handle/10283/3105. Some of the 
individual trial data are separately available as follows: 
IST-3 - https://datashare.is.ed.ac.uk/handle/10283/1931; RESTART 
- https://datashare.is.ed.ac.uk/handle/10283/3265.
Conclusions
RITeS will provide robust but fair independent testing of 
e-ASPECTS and e-CTA software from Brainomix measured 
against the current gold standard for CT imaging assessment, 
expert-human interpretation.
This statistical analysis plan pre-specifies all methods prior to 
un-blinding and analysis of RITeS data.
Data availability
Underlying data
No underlying data are associated with this article.
Reporting guidelines
Edinburgh Datashare: Statistical Analysis Plan checklist 
for ‘Real-world Independent Testing of e-ASPECTS Soft-
ware (RITeS): statistical analysis plan’. https://doi.org/10.7488/
ds/280355.
The completed reporting guidelines checklist is available under 
the terms of the Creative Commons Attribution 4.0 International 
license (CC-BY 4.0).
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The authors and wider RITeS study research team declare 
that Brainomix Ltd, their staff and other affiliated individu-
als have not been involved in the creation of this research plan 
or the setting of the RITeS aims and objectives. Image process-
ing, analysis, interpretation and dissemination of results will be 
conducted independent of Brainomix Ltd and its affiliates.
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